Summer!2016! Undergraduate! Research! Internships!
|
|
|
- Posy Grant
- 5 years ago
- Views:
Transcription
1 Summer2016 Undergraduate Research Internships Qualifications:- 1.18yearsofageorolder. 2.MustattendPLU,SeattleU,SPUorbealocalundergraduatemilitaryveteran. 3.EnteringjuniororpreferablysenioryearinFall DeclaredBiology/CMOL/MCONorBiochemistryasamajor;7"labs"will"take"students. One"position"in"the"Schiffer"lab"is"available"for"a"major"in:"math,-physics,-or-engineering." 5.Minimumoftwowetlabcourseswith"emphasis"on"pipetting,"PCR,"sterile"technique," recording"in"a"lab"notebook,"proficient"in"ms"office"programs,"and"youareinterestedin researchasafuturecareer. 6.Tworecommendationlettersfromscienceprofessors. 7.ComfortableworkingwithBiohazardousmaterials:HIV,"HSV,"FLU"and"bacteria." Applyonlineatwww.fredhutch.org/en/careers.html Please"submit"your"resume"and"a"cover"letter"explaining"why"you"are"interested"in"research"and"what" laboratory"you"prefer"to"work"in"this"summer."you"will"also"need"two"letters"of"recommendations"from" science"professors."this"is"an"unpaid"internship,"and"if"you"would"like"to"get"credit"from"your"university," please"let"us"know"in"the"interview."undergraduatemilitaryveteransarestronglyencouragedtoapply."" Internship"will"begin"in"midMJune"and"last"at"least"nine"weeks." Deadline:April15,2016 To"view"the"list"of"labs"who"will"take"interns"in"Summer"2016"(if$site$is$updated):" " This"page"and"lab"info"also"are"provided"as"a"link"from"the"SU"Biology"homepage:"
2 Summer program outline Length of internship The program is 9 weeks and depending on your schedule it could be a few weeks more if you choose. The 1 st day you will sit down with me to go over expecta?ons and your role in the lab. You will then go to your assigned lab for the summer and meet with the person(s) who will supervise you. 1 st two weeks The 1 st two weeks will entail comple?ng paperwork, ini?al safety trainings. If you are working with mice there are tests to complete and training to enter the facility. - HR paperwork & badges - Lab safety training - Blood borne pathogen training - Mouse training & tests Fred Hutchinson Cancer Research Center 5
3 2016 labs Lund Lab- Dr. Jennifer Lund: The focus of the Lund lab is on elucida?ng the basic mechanisms of immunity in the context of virus infec?on. Specifically, we use a mouse model to study how regulatory T- cells affect the an?- viral immune responses to genital HSV- 2, influenza, and West Nile virus. Prlic Lab- Dr. Mar?n Prlic: The Prlic lab studies 2 popula?ons of the immune system, CD8 T cells and NK cells, using in vivo (mouse) and in vitro model systems. Our goal is to understand the molecular basis of cell ac?va?on and differen?a?on to learn how to manipulate the cells for therapeu?c purposes. Taylor Lab- Dr. Jus?n Taylor: Mechanisms driving the differen?a?on of B cells following vaccina?on and infec?on. Understanding how differences in the pre- immune repertoire influences immunity Vaccine Development. HVTN: The HIV Vaccine Trials Network (HVTN) is the world s largest publicly funded mul?- disciplinary interna?onal collabora?on facilita?ng the development of vaccines to prevent HIV/ AIDS. The HVTN conducts all phases of clinical trials, from evalua?ng experimental vaccines for safety and immunogenicity to tes?ng vaccine efficacy. Fred Hutchinson Cancer Research Center 2
4 Labs con?nued McElrath Lab: Dr. Julie McElrath: The McElrath laboratory applies mul?- disciplinary and cross- plaeorm approaches to their studies, which encompass the following research areas: HIV Vaccine Trials Network (HVTN) Laboratory HVTN Cape Town Lab Seafle HIV Vaccine Trials Unit (Seafle HVTU) Collabora?on for AIDS Vaccine Discovery (CAVD) - 3 projects Malaria & Tuberculosis Vaccines CHAVI- ID Long Term Non- Progressor Cohort (LTNP) Schiffer Lab- Dr. Josh Schiffer: The aim of my group is to characterize quan?ta?ve features of human pathogens and immune responses. Ul?mately, we are most interested in iden?fying thresholds at which infec?ons either take off leading to disease and transmission, or are contained by the human immune system. This fundamental ques?on is highly per?nent to vaccine and an?viral therapy development. Fred Hutchinson Cancer Research Center 3
5 Labs Con?nued. Corey Lab- Dr. Larry Corey: The Corey Lab inves?gates the underlying mechanisms between herpes simplex virus pathogenesis and the host immune response. Specifically, the associa?ons between HSV- 2 disease severity and the quan?ty, quality and diversity of?ssue resident memory CD8+ T cells persis?ng amer HSV- 2 reac?va?on in humans. The research focus of this posi?on is the study of an?body response generated during natural Herpes Simplex Virus Type 2 infec?on and during vaccina?on procedures. This posi?on would be primarily responsible for developing and performing an?body- dependent cellular phagocytosis assays to measure phagocy?c ac?vity of an?bodies. The summer student will also be responsible for general laboratory maintenance including sample receipt and logging, reagent prepara?on, supply stocking, autoclaving, emptying biohazard waste and maintaining laboratory equipment. Our lab focuses on the immune response mounted against HSV- 2 by T cells resident in the skin. If you join us you will be working on determining the viral epitopes recognized by these T cells, knowledge which would be important in designing vaccines and therapies in the future. You will learn commonly u?lized skills including molecular biology,?ssue culture and T cell func?onal assays. Compara?ve Medicine- Jamie Nguyen: Under the instruc?on of the Compara?ve Medicine Imaging Technician, the intern will learn how to scan mice in the small animal MRI and all procedures associated with it (anesthesia, IV/IP injec?on, etc.). Amer ini?al skills have been mastered the intern would be responsible for acquiring MR images to meet deadlines and independently troubleshoot common issues with the complex imaging equipment. Fred Hutchinson Cancer Research Center 4
For personal use only
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 22 November 2016 The Manager Companies ASX Limited
Induction of Innate Immune Responses in HVTN 071: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study
Induction of Innate Immune Responses in HVTN 71: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study Erica Andersen-Nissen Vaccine and Infectious Disease Institute Fred Hutchinson Cancer Research
PATRICK ANSAH PRINCIPAL INVESTIGATOR 22/02/2016
Evaluation of the Men A specific antibody persistence in Ghanaian children more than five years after immunization with PsA-TT (2.5 μg, 5 μg, or 10 μg polysaccharide concentration) PATRICK ANSAH PRINCIPAL
BIOTRON LIMITED (ASX:BIT) Biotech Showcase 2017
BIOTRON LIMITED (ASX:BIT) Biotech Showcase 2017 Forward Looking Statements This presenta,on may contain forward-looking statements with respect to the financial condi,on, results and business achievements/performance
Outbreak response in post- OPV2 withdrawal era. Strategic Advisory Group of Experts (SAGE) on immuniza;on, Geneva, 22 October 2014
Outbreak response in post- OPV2 withdrawal era Strategic Advisory Group of Experts (SAGE) on immuniza;on, Geneva, 22 October 2014 Request to SAGE Endorse the principles for outbreak response in post- OPV2
HVTN Laboratory Program: Immunogenicity and Research Assays
HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,
WHO posi)on paper on hepa))s A vaccines
WHO posi)on paper on hepa))s A vaccines Geneva, Switzerland Published in the Weekly Epidemiological Record on 13 July 2012 Transmission and incidence Hepa))s A virus (HAV) is transmiled primarily via the
WHO position paper on meningococcal vaccines
WHO position paper on meningococcal vaccines Geneva, Switzerland Published in WER Nov 2011 Epidemiology of meningococcal disease In most countries Neisseria meningi+dis is a leading cause of meningi)s
Physiology Unit 3 THE SPECIFIC IMMUNE RESPONSE
Physiology Unit 3 THE SPECIFIC IMMUNE RESPONSE The Adap4ve Arm of the Immune System Specific Immune Response Internal defense against a specific pathogen Acquired as you are exposed to diseases The immune
B and T cell Memory. Bengt Lindbom Adap6ve Immunity BMC D14
B and T cell Memory Bengt Lindbom Adap6ve Immunity BMC D14 Immunity: a historical perspec6ve 430 B.C. Thucydides describes the ongoing plague of Athens:.the same man was never attacked twice 15th century:
Field research to iden/fy infec/ous agents in animals and the environment to a6empt to predict emergence
Field research to iden/fy infec/ous agents in animals and the environment to a6empt to predict emergence John S Mackenzie Plenary session 3: Policies and Strategies to Meet the Challenge of Emerging Disease
Recrea&onal Therapy. Thomas K. Skalko, Ph.D., LRT/CTRS Chair, Commi<ee on Accredita&on of Recrea&onal Therapy Educa&on
Recrea&onal Therapy Thomas K. Skalko, Ph.D., LRT/CTRS Chair, Commi
Paget s Disease of Bone
Paget s Disease of Bone Copyright Copyright 2019 American 2019 American Associa7on Associa7on of Clinical of Clinical Endocrinologists Endocrinologists 1 A Common Bone Disorder Paget s disease of bone
Introduction to Microbes and Infectious Disease
Name: Date: Introduction to Microbes and Infectious Disease Station 1) Pathogens Pathogens are capable of causing. Examples: Station 3) Discovery My name is Anton von Leeuwenhoek, and in I documented my
Introduction. Objectives. Risk Classification. Biologic Hazards
Occupational Medicine Residency at WVU 2 Year program (after internship) AOA & ACGME Accredited Only AOA program in OEM Includes MPH (or soon MOH) degree Based in Morgantown, WV NIOSH (DRDS, DSR, and HELD)
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC and its technical Directives (particularly 2006/17/EC) More stringent -legally binding, applies for all donations and all donor profiles
Secondary Zika virus infection do not support evidences of Antibody-Dependent Enhancement in vivo in dengue pre-exposed rhesus macaques
University of Puerto Rico Medical Sciences Campus Caribbean Primate Research Center Secondary Zika virus infection do not support evidences of Antibody-Dependent Enhancement in vivo in dengue pre-exposed
AREAS OF CONCENTRATION
Dr. Shruti Mehta, Director The development of antibiotics, improved access to safe food, clean water, sewage disposal and vaccines has led to dramatic progress in controlling infectious diseases. Despite
SPPH Control of Communicable Diseases January - April 2018
SPPH 520 - Control of Communicable Diseases January - April 2018 TIME: LOCATION: INSTRUCTORS: OFFICE: ASSISTANT: Mondays, 9:00AM- 12:00PM Room 143, School of Population and Public Health Bldg Dr. David
CONTACTS & ACKNOWLEDGEMENTS
CONTACTS & ACKNOWLEDGEMENTS Snohomish Health District Communicable Disease Surveillance and Response Analysis and publication: Hollianne Bruce, MPH Program Manager: Amy Blanchard, RN, BSN Communicable
IMMUNE RESPONSE TO INFECTIOUS DISEASES
IMMUNE RESPONSE TO INFECTIOUS DISEASES Immune Response to Bacterial Infection Characteris*cs of Bacteria 1 X 2 X 3 X 4 X 5 X 6 X 7 X Bacterial Diseases Any part of the body can be infected by many Infec;ous
How are Blood borne pathogens harmful? How do you come into contact with Blood-borne pathogens?
What are Blood borne pathogens? How are Blood borne pathogens harmful? How do you come into contact with Blood-borne pathogens? How do I protect myself? A blood-borne disease is one that can be spread
BIOTRON LIMITED (ASX:BIT) Broker Meet Biotech August 2018
BIOTRON LIMITED (ASX:BIT) Broker Meet Biotech August 2018 Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au Forward Looking Statements This presenta8on may contain
Tricks in HIV s bag to counter vaginal or rectal microbicides
Tricks in HIV s bag to counter vaginal or rectal microbicides Florian Hladik, MD, PhD University of Washington Fred Hutchinson Cancer Research Center Seattle Contribution of the various HIV invasion routes
IMPAACT TB SCIENTIFIC COMMITTEE. Anneke C Hesseling: Chair Sharon Nachman: Interim Vice Chair IMPAACT Vice Chair
IMPAACT TB SCIENTIFIC COMMITTEE Anneke C Hesseling: Chair Sharon Nachman: Interim Vice Chair IMPAACT Vice Chair Goal Address cri>cal therapeu>c research gaps in the preven>on and treatment of tuberculosis
PRESENTATION AT BIOTECH INVEST 2016
4 May 2016 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website:
Handling Sharps. By: Jennifer Adams RN PHN Harm Reduction PHN Coordinator
Handling Sharps By: Jennifer Adams RN PHN Harm Reduction PHN Coordinator What is a Sharp? Sharps that can cause injury and expose workers to dangerous pathogens include: Hypodermic Needles Blood collection
Transfusion Medicine Kris0ne Kra1s, M.D.
Transfusion Medicine Kris0ne Kra1s, M.D. Transfusion Medicine Outline Blood groups Introduc0on ABO system Rh system Other systems Blood transfusion Blood products Indica0ons Tes0ng Dangers Transfusion
In developed countries (like the U.S.) we really only have to worry about viruses and bacteria
The immune system dis1nguishes self from non- self When we think of the immune system, we o>en only think that it protects us from pathogens (bacteria, viruses, fungi, parasites) But, the immune system
Healthcare Professionals
EMPLOYEE HEALTH Employee Health: Screening and immunization programs Counseling, follow up work restrictions Analysis and trending of occupational exposure incidents Assess risk for occupational exposure
IN VIVO STUDIES ON VIRAL VIRULENCE
IN VIVO STUDIES ON VIRAL VIRULENCE M.Phil student: Emily TSUI Supervisor: Professor Paul K.S Chan Department of Microbiology, CUHK Date: 15th Dec, 2014 Viral Virulence Capacity of a virus to cause disease
Chapter 22. Immunity
Chapter 22 Immunity Body Defenses-Immunity The Lympha6c System and Body Defenses Body defenses provide resistance to fight infec6on, illness, and disease Two categories of defenses 1. Innate (nonspecific)
WHO posi)on paper on influenza vaccines*
WHO posi)on paper on influenza vaccines* Geneva, Switzerland Published in the Weekly Epidemiological Record on 23 November 2012 * This posi(on paper is concerned mainly with vaccines and vaccina(on against
Non-reproductive tissues and cells
Colour key Tested pathogen VIRAL Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legy binding on national level More stringent testing - recommended on national level Not
Laboratory Services and Networks Your priorities?
12th Meeting Caribbean National Epidemiologists and Laboratory Directors September 17th-19th, 2014 POS, Trinidad and Tobago Laboratory Services and Networks Your priorities? Dr Cristina Gutierrez Laboratory
Nothing to disclose. Screening for and treatment of Hepa11s B and C 2/18/15
Screening for and treatment of Hepa11s B and C Lisa Winston, MD University of California, San Francisco San Francisco General Hospital Nothing to disclose. 1 Hepa11s B Epidemiology Pathogenesis Lecture
WHO posi)on paper on pneumococcal vaccines. Geneva, Switzerland Published in the Weekly Epidemiological Record on 6 Apr 2012
WHO posi)on paper on pneumococcal vaccines Geneva, Switzerland Published in the Weekly Epidemiological Record on 6 Apr 2012 WHO posi)on paper on pneumococcal vaccines, April 2012 The current posi)on paper
Application of systems biology to identify predictors of HIV vaccine immunogenicity
Application of systems biology to identify predictors of HIV vaccine immunogenicity Daniel Zak 1, Erica Andersen-Nissen 2, Haesun Park 3, Scott Hansen 3, Karl Mullen 3, Kristi Hamilton 1, Kathleen Kennedy
Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary
Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary The President s FY 2009 Budget Request for the Centers for Disease Control and Prevention (CDC) discretionary funding is
SPPH Control of Communicable Diseases January - April 2016
SPPH 520 - Control of Communicable Diseases January - April 2016 TIME: LOCATION: INSTRUCTORS: OFFICE: ASSISTANT: Mondays, 9:00AM- 12:00PM Room 143, School of Population and Public Health Bldg Dr. David
Nova StatStrip Blood Glucose Meter Re-Cer7fica7on 2017
SUNY Downstate Medical Center University Hospital of Brooklyn Point of Care Laboratory & Department of Nursing Services Ins7tute of Con7nuous Learning Nova StatStrip Blood Glucose Meter Re-Cer7fica7on
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS APRIL 2017 Infectious viruses are a global health threat Since the approval of the first antiviral drug
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS MAY 2017 1 Infectious viral pathogens are a significant global health threat to mankind 2 Since the approval
Assisted Living s Whole Brain Fitness: Can It Prevent Re-hospitalization?
Assisted Living s Whole Brain Fitness: Can It Prevent Re-hospitalization? Health Care Environment Is Changing, Opening Up New Opportuni:es for Assisted Living Center for Medicaid & Medicare Services (CMS)
Bloodborne Pathogens. Exposure Control Plan
Bloodborne Pathogens Exposure Control Plan Maryland Institute College of Art Revision Date(s): January 2007/January 2008 Maryland Institute College of Art (MICA) Subject: Occupational/Non-occupational
HIV acute infections and elite controllers- what can we learn?
HIV acute infections and elite controllers- what can we learn? Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) and HIV Pathogenesis Programme (HPP), Doris Duke
The White Re)na. Joseph Alsberge, MD January 20, 2018
The White Re)na Joseph Alsberge, MD January 20, 2018 58 y/o man with floaters and pain OD x 2 weeks PMH: oral and genital herpes Va OD 20/50 Anterior OD: KP and 3+ AC cell Posterior: Vitri)s, occlusive
Preventing Infections in the Era of Biologics
Preventing Infections in the Era of Biologics Deepali Kumar MD MSc FRCPC Immunocompromised Infectious Diseases Program University Health Network Toronto Disclosure Research Grants Roche, GSK Honoraria
OSHA Inservice. UEMS Occupational and Travel Health Lisa Fincher Mergi MS ARNP-BC FNP SANE-A
OSHA Inservice UEMS Occupational and Travel Health Lisa Fincher Mergi MS ARNP-BC FNP SANE-A What does OSHA stand for? Occupational Safety and Health Administration OSHA requires all potentially occupationally
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding on national level More stringent - recommended on national level Not legy binding and not recommended on
Infection Control. Why Bother? Leslie Roste, RN
Infection Control. Why Bother? Leslie Roste, RN Introduction Leslie Roste, RN Healthcare Background Infection Control Labor& Delivery Emergency Department Education Nursing Microbiology National Director
Identifying Engineering, Clinical and Patient's Metrics for Evaluating and Quantifying Performance of Brain- Machine Interface Systems
Identifying Engineering, Clinical and Patient's Metrics for Evaluating and Quantifying Performance of Brain- Machine Interface Systems Jose Pepe L. Contreras-Vidal, Ph.D. Department of Electrical & Computer
Na#onal HPV Vaccina#on Roundtable. Noel Brewer, Chair Debbie Saslow, Vice- Chair
Na#onal HPV Vaccina#on Roundtable Noel Brewer, Chair Debbie Saslow, Vice- Chair Mission The Na'onal HPV Vaccina'on Roundtable is a na'onal coali'on of public, private, and voluntary organiza'ons and invited
SECTION 1: ABOUT HEPATITIS
SECTION 1: ABOUT HEPATITIS Hepa33s Means Swollen Liver Many things can cause your liver to become swollen, including drinking a lot of alcohol; taking certain medica3ons or herbs; inhaling toxic fumes;
LAI: Linee guida ed esperienze internazionali
LAI: Linee guida ed esperienze internazionali LAI: Guidelines and interna5onal experience PM Llorca CHU Clermont-Ferrand EA 7280 Université Clermont Auvergne Disclosures Advisory board: Allergan, Jansen,
Laboratory Survey Results. Preventing disease, promoting and protecting health
Laboratory Survey Results Laboratory Survey 211 1 Bacteriology Laboratory Capacity in Twenty (2) CMC Percentage% Capacity 8 6 4 2 Campylobacter Cholera E. coli Leptospirosis N. meningitidis H. influenzae
City of Montpelier, Vermont The Smallest Capital City in the United States BLOODBORNE PATHOGENS EXPOSURE CONTROL PLAN AND PROCEDURES
City of Montpelier, Vermont The Smallest Capital City in the United States BLOODBORNE PATHOGENS EXPOSURE CONTROL PLAN AND PROCEDURES Last Updated June 19, 2003 1 Bloodborne Pathogens Exposure Control Plan
B. Tasks and Procedures where employees, students or contractors can be exposed to bloodborne pathogens:
Page 1 of 6 BLOODBORNE PATHOGEN PROGRAM INTRODUCTION The intended purpose of this document is to comply with OSHA s Occupational Exposures to Bloodborne Pathogens in Title 29 Code of Federal Regulations
Infectious Disease Epidemiology BMTRY 713 January 11, 2016 Lectures 2 Continuation of Introduction & Overview
Infectious Disease Epidemiology BMTRY 713 Lectures 2 Continuation of Introduction & Overview Learning Objectives 1. Explain the magnitude of infectious diseases 2. Describe major principles in infectious
Bloodborne Pathogens
Bloodborne Pathogens Session Objectives Identify bloodborne pathogens (BBPs) Understand how diseases are transmitted Risk of exposure Protecting yourself from exposure through prevention Responding appropriately
New Fron)ers in Therapies for Autoimmunity
New Fron)ers in Therapies for Autoimmunity Preview Discuss spectrum of autoimmune research at MUSC Iden)fy some of the key inves)gators in basic and clinical research at MUSC Discuss specific areas of
FOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1
1 Immunological tolerance and immune regulation -- 1 Abul K. Abbas UCSF FOCiS 2 Lecture outline Principles of immune regulation Self-tolerance; mechanisms of central and peripheral tolerance Inhibitory
SECTION 1: ABOUT HEPATITIS
SECTION 1: ABOUT HEPATITIS Hepa33s means swollen liver Many things can cause your liver to become swollen, including drinking a lot of alcohol; taking certain medica3ons or herbs; inhaling toxic fumes;
APPROVED AT REGIONAL COUNCIL September 13,201 2
Region of Peel APPROVED AT REGIONAL COUNCIL September 13,201 2 HE-6. INTERDEPARTMENTAL HE-Bl. Health in Peel: Communicable Disease, 2006-2010 Presentation by Dr. Eileen de Villa, Associate Medical Officer
Transfusion Medicine Kris0ne Kra1s, M.D.
Transfusion Medicine Kris0ne Kra1s, M.D. Transfusion Medicine Outline Blood groups Introduc0on ABO system Rh system Other systems Blood transfusion Blood products Tes0ng Dangers Transfusion Medicine Outline
Mandatory Flu Vaccine Policy Colleague Questions and Answers as of September 5, 2017
2017-2018 Mandatory Flu Vaccine Policy Colleague Questions and Answers as of September 5, 2017 Why are we being mandated to get a flu shot? According to the CDC, annual hospitalizations in the U.S. attributed
EPIDEMIOLOGY (EPI) Kent State University Catalog
Kent State University Catalog 2018-2019 1 EPIDEMIOLOGY (EPI) EPI 50013 CLINICAL EPIDEMIOLOGY BASICS 3 (Cross-listed with PH 40013) The purpose of this course is to develop an understanding of clinical
Halton Region Health Department Vol 13, Issue 2 Summer 2006 To all Halton Physicians The following topics are included in this update: West Nile Virus Update Update on Mumps Hepatitis B Immunization for
Quo/ent Limited 34 th Annual J.P. Morgan Healthcare Conference
Quo/ent Limited 34 th Annual J.P. Morgan Healthcare Conference MosaiQ - Advancing to Commercializa/on January 13, 2016 Transforming transfusion diagnos/cs. Safe Harbor Statement This presenta/on contains
The Canadian Landscape of PaAent Reported Outcome and Experience Measures. Santana MJ, MPharm, PhD October 17, 2016, Amsterdam
The Canadian Landscape of PaAent Reported Outcome and Experience Measures Santana MJ, MPharm, PhD October 17, 2016, Amsterdam Canada & Netherlands: The Tulip Legacy Outline Overview -- Na+onal strategy
Pa$ent w/ HCV 5/26/2016
Ini$al of a Evalua$on(s) Pa$ent w/ HCV 5/26/2016 Objec$ves To discuss the issues involved in the ini/al encounters of a pa/ent w/ Hepa//s C Learning how to provide pa/ent educa/on about hepa//s C transmission,
Update on Adult Immunizations and Recommendations
Update on Adult Immunizations and Recommendations NMSHP BALLOON FIESTA MEETING OCTOBER 4, 2015 JENNIFER BLAKE, PHARMD BCPS CLINICAL PHARMACY SUPERVISOR, VA MEDICAL CENTER Objectives - Pharmacist Describe
PROCEDURE TITLE: BLOOD BORNE PATHOGENS EXPOSURE CONTROL PLAN PROCEDURE NO.: 5.21:1
PROCEDURE TITLE: BLOOD BORNE PATHOGENS EXPOSURE CONTROL PLAN PROCEDURE NO.: 5.21:1 RELATED POLICY: 5.21REV PAGE NO.: 1 OF 9 RESPONSIBLE ADMINISTRATOR(S): VPF&A/EHS EFECTIVE DATE: 07/11/14 NEXT REVIEW DATE:
Canine Atopic Derma//s and the IL-31 Inhibitors
Canine Atopic Derma//s and the IL-31 Inhibitors Daniel O. Morris, DVM, MPH, DACVD Professor of Dermatology & Allergy School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA DISCLOSURE
JAY A. NELSON, PH.D. Executive Director and Vice President
JAY A. NELSON, PH.D. Executive Director and Vice President TRANSLATING RESEARCH INTO HEALTH Jay A. Nelson, Ph.D., is the founder and Executive Director of Vaccine & Gene Therapy Institute of Florida (VGTI-FL)
Emerging gene)cs in schizophrenia: Real challenges for crea)ng animal models
Emerging gene)cs in schizophrenia: Real challenges for crea)ng animal models Steven A McCarroll, PhD Stanley Center for Psychiatric Research, Broad Ins7tute Department of Gene7cs, Harvard Medical School
DOWNLOAD OR READ : THE VIRUS PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : THE VIRUS PDF EBOOK EPUB MOBI Page 1 Page 2 the virus the virus pdf the virus West Nile virus (WNV) is the leading cause of mosquito-borne disease in the continental United States. It
Molecular Diagnos/cs has emerged as one of the largest and fastest growing segments in the $54 billion in-vitro diagnos/c (IVD) industry.
Molecular Diagnos/cs has emerged as one of the largest and fastest growing segments in the $54 billion in-vitro diagnos/c (IVD) industry. 10 The 5 largest segments of the IVD market are Central Lab Immunoassays,
National Health & Medical Research Council (NHMRC) Results Fellowships and Australia/European Union Collaborative Grants Scheme 2018
National Health & Medical Research Council (NHMRC) Results Fellowships and Australia/European Union Collaborative Grants Scheme 2018 The NHMRC has publically released results (embargo lifted on 11 October
Conflicts of interest. Objec5ves / Outline. Pulmonary rehabilita5on. Pulmonary rehabilita5on in COPD. Pulmonary rehabilita5on in COPD 11/26/13
Conflicts of interest UBC I have no conflicts of interest related to this presenta5on Treatment op+ons From a global perspec+ve: Non- pharmaceu+cal treatments Pulmonary Fibrosis Founda5on Summit La Jolla,
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More stringent - recommended Not legy binding and not recommended Tested pathogen Donor test/ technique
Communicable Diseases
Chapter 23 Communicable Diseases Disease that s spread from one living organism to another or through the environment Infection occurs when pathogens in the body multiply and damage body cells Main Pathogens
Conflicts of interest. Pulmonary rehabilita8on. Objec8ves / Outline. Pulmonary rehabilita8on in COPD. Pulmonary rehabilita8on in COPD
Conflicts of interest UBC I have no conflicts of interest related to this presenta8on Treatment op+ons From a global perspec+ve: Non- pharmaceu+cal treatments Pulmonary Fibrosis Founda8on Summit La Jolla,
Hospital Communicable Diseases Surveillance Protocols Primer. Key Infec:on Preven:on and Control Lapses in the Clinical Office
OEMAC 33 rd Scien/fic Conference September 29, 2015; 2:50-3:15 Hospital Communicable Diseases Surveillance Protocols Primer Key Infec:on Preven:on and Control Lapses in the Clinical Office Se@ng Dr. Maureen
Preven&ng Pertussis: Current and Needed Strategies. June 16, PM 8PM
Preven&ng Pertussis: Current and Needed Strategies June 16, 2016 6PM 8PM Acknowledgements Agenda Welcome and Introduc&ons Epidemiology of Pertussis Essi M. Havor, MSN, APHN, RN Houston Health Department
Orientation Program for Infection Control Professionals
Orientation Program for Infection Control Professionals Module 7: Communicable Diseases Table of Contents Module 7: Communicable Diseases... 1 Objectives... 1 Instructions... 1 Overview... 2 Key Concepts...
Hepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D
Hepatitis B HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, 2016 Lalo Flores, PhD Global Head HBV R&D Infectious Diseases Diseases Infectious 11 Janssen s Vision
Defining and Studying RetenLon in pre- ART Care for HIV Infected Adults in sub- Saharan Africa
Defining and Studying RetenLon in pre- ART Care for HIV Infected Adults in sub- Saharan Africa Ma$hew Fox & Sydney Rosen Center for Global Health & Development Boston University mfox@bu.edu July 15, 2011
Resolving the PSA testing controversy. Professor Villis Marshall AC Professor Bruce Armstrong AM Professor Mark Frydenberg
Resolving the PSA testing controversy Professor Villis Marshall AC Professor Bruce Armstrong AM Professor Mark Frydenberg Professor Villis Marshall AC Introduc)on Guidelines aim to inform tes)ng for the
Facility and Management
Training Course of Microbial Resources Information Management and Utilization for Developing Countries BSL-3 Laboratory Facility and Management Dr. Yiping Zhu Sep. 14 2016 Pathogens and BSL-3 laboratory
Blood borne Pathogen Exposure Policy for Students
Blood borne Pathogen Exposure Policy for Students A University of Rhode Island (URI) student or intern who sustains an exposure from a needle stick, instrument stick, or mucous membranes to non-intact
Disseminated shingles acyclovir
Disseminated shingles acyclovir The Borg System is 100 % Disseminated shingles acyclovir Two developed disseminated herpes zoster, one developed cytomegalovirus. Reduced response to acyclovir,. Disseminated
HIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
Disclosures. Immuniza(on Update Vaccina(ng All Ages. Learning Objec(ves. Test Your Knowledge. Test Your Knowledge. Test Your Knowledge 4/28/17
Immuniza(on Update 2017 - Vaccina(ng All Ages Jayme Garcia, PharmD Pa#ent Care Coordinator Smith s Food & Drug UPhA Board Member Disclosures Dr. Garcia declares no conflicts of interest, real or apparent,
Building Capacity to Support Children With Hearing Loss in Vietnam
Building Capacity to Support Children With Hearing Loss in Vietnam Paige Stringer, M.A. Founder and Executive Director Global Foundation For Children With Hearing Loss May 3, 2013 Sta>s>cs: World Bank
Biosafety Basics. Patrick Stockton, Director, Office of Biosafety Biosafety Community Liaison Committee June 26, 2017
Biosafety Basics Patrick Stockton, Director, Office of Biosafety Biosafety Community Liaison Committee June 26, 2017 What is Biosafety? The discipline that addresses how to provide guidance and assistance
Using Implementation Science to Address Prevention of Mother to Child Transmission of HIV
Using Implementation Science to Address Prevention of Mother to Child Transmission of HIV Dr. Laura Guay Vice President for Research Elizabeth Glaser Pediatric AIDS Founda@on 1 The role of Implementation
NIAID Vaccine Research Center: A Mission to Prevent HIV Infection
NIAID Vaccine Research Center: A Mission to Prevent HIV Infection AIDS Vaccine Awareness Day 20 year anniversary May 18, 2017 Barney S. Graham, MD, PhD Deputy Director Origins of the VRC 1997 1998
Knox County Health Department. COMMUNICABLE DISEASE REPORT: January 2018 YTD
COMMUNICABLE DISEASE REPORT: January This report contains informaon regarding suspected, probable, and confirmed cases of the diseases listed and are subject to change. Ohio Disease Reporng System (ODRS)
Designing An)gen- specific Immunotherapy for Treatment of Type 1 Diabetes.
Designing An)gen- specific Immunotherapy for Treatment of Type 1 Diabetes. Kristin V. Tarbell Immune Tolerance Unit, Diabetes Endocrinology and Obesity Branch, NIDDK Outline Background on type 1 diabetes